Tags : Develop

BMS Signs a Five-Year Agreement with Insitro to Develop Therapies

Shots: Insitro to receive $50M as up front, $20M as near-term operational milestones and is eligible to receive ~$2B+ as discovery, development, regulatory and commercial milestones along with royalties on sales of the therapies BMS will lead the clinical development, regulatory submissions, and commercialization activities. Insitro will apply its insitro Human (ISH) platform, to create […]Read More

Novartis Signs an Option and License Agreement with Molecular Partners

Shots: Molecular Partners to receive $65.8M as up front, including equity, and will receive $164.7M as an option payment for both MP0420 and MP0423 along with royalties on sales of therapies. Novartis to get an option to in-license global rights of MP0420 and MP0423 During the option period, Molecular Partners will conduct a P-I study […]Read More

Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

Shots: The companies will collaborate to develop, manufacture, and distribute AT-527 to combat COVID-19. If approved, Atea will be responsible for distributing the treatment option in the US, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the US The therapy is currently being evaluated in P-II study for […]Read More

Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19

Shots: The companies collaborate for fast-track development of DNP-019 against COVID-19 The collaboration will expand Samsung’s CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing Samsung has introduced its proprietary cell-line technology, S-CHOice, demonstrating improved titers up to two-fold and maintaining […]Read More

ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize

Shots: ImmunoGen to receive $40M up front, ~$265M as development, regulatory & commercial milestones and is eligible to receive royalties on sales of mirvetuximab in Greater China and will retain all rights to mirvetuximab in the US & ROW The collaboration accelerates the development path for mirvetuximab in Greater China and expands Huadong’s oncology portfolio […]Read More

Henlius Signs a License Agreement with Essex to Co-develop HLX04

Shots: Henlius to receive upfront, regulatory, and commercial milestone payments of ~$43M, eligible to receive $30M for every $1B above the first $600M of the cumulative net sales along with 10% royalties on net sales of the therapy Henlius will be responsible for the pre/ clinical development of HLX04, whereas Essex is responsible for regulatory […]Read More

Roche Signs a License Agreement with Dyno to Develop AVV

Shots: Dyno to receive upfront and is eligible to receive ~$1.8B milestones including development and commercial milestones along with royalties on any product emerges during the collaboration Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy while Roche and Spark will conduct preclinical, clinical, and commercialization […]Read More

Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1

Shots: Arrowhead to receive ~$300M up front, ~$740M as development, regulatory and commercial milestones and is eligible to receive royalties of 20-25% on net sales If approved, the companies will co-develop ARO-AAT and co-commercialize it in the US, under 50/50 profit sharing structure. Additionally, Takeda will lead the global commercialization strategy and get an exclusive […]Read More

Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung

Shots: The agreement leverages Imbio’s technical, regulatory & commercial expertise to build medical imaging AI technology for use in research, clinical trials & clinical practice The focus of the agreement is to develop quantitative imaging diagnostics for lung diseases and to bring unique solutions for pulmonary imaging. The collaboration integrates Imbio’s expertise in imaging biomarkers […]Read More

Novartis and Siemens Collaborate to Develop Blood Tests for Multiple

Shots: The companies enter in a master agreement to design, develop, and commercialize diagnostic tests for therapies Novartis’ therapeutic pipeline The collaboration will initially focus on the development of serum neurofilament light chain (NfL) immunoassay for patients with MS and other neurological diseases Siemens will leverage its expertise in the development of clinical diagnostic solutions […]Read More